Dishman Carbogen

What does Dishman Carbogen do?

Dishman Carbogen Amcis Ltd provides Contract Research and Manufacturing Services in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of ₹716 Cr and a net profit of ₹43 Cr, with a market cap of ₹4,226 Cr.

Overview:<BR>Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) within the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The company was incorporated as Carbogen Amcis (India) Limited in 2007 and later changed its name to Dishman Carbogen Amcis Limited on March 27, 2017. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 716 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 43 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 4,226 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 191.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.32<BR>- Return on Equity: 0.38%<BR>- Price to Book: 0.73<BR><BR>Contact Details:<BR>Address: Dishman Corporate House, Iscon-Bopal Road Ambli Ahmedabad Gujarat : 380058<BR>Tel: 91-2717-400102/124<BR>Email: grievance@dishmangroup.com<BR>Website: htts://imdcal.com

Has Dishman Carbogen declared dividend?

Dishman Carbogen Amcis Ltd has declared a 10% dividend, amounting to ₹0.2 per share, with an ex-date of September 12, 2019. However, there have been no dividends declared since then, resulting in a 0% dividend return across multiple periods despite significant price returns.

Dishman Carbogen Amcis Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 0.2<BR>- Ex-date: 12 Sep 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -0.48%, the dividend return was 0%, resulting in a total return of -0.48%.<BR><BR>Over the past year, the price return was 85.25%, with a dividend return of 0%, leading to a total return of 85.25%.<BR><BR>In the last 2 years, the price return was 116.96%, while the dividend return remained at 0%, culminating in a total return of 116.96%.<BR><BR>For the 3-year period, the price return was 124.29%, with a dividend return of 0%, resulting in a total return of 124.29%.<BR><BR>In the 4-year period, the price return was 27.47%, and the dividend return was 0%, leading to a total return of 27.47%.<BR><BR>Over the last 5 years, the price return was 273.97%, with a dividend return of 0%, resulting in a total return of 273.97%.<BR><BR>Overall, Dishman Carbogen has declared a dividend in the past, but there have been no dividends declared since then, as indicated by the 0% dividend return across multiple periods. The company has shown significant price returns over the years, particularly in the 5-year period, despite the absence of recent dividends.

Who are the peers of the Dishman Carbogen?

Dishman Carbogen's peers include Aarti Drugs, Sequent Science, Hikal, Unichem Labs, RPG LifeScience, Gujarat Themis Bio, Orchid Pharma, Gufic BioScience, and Advanced Enzyme. RPG LifeScience shows excellent management risk and the highest 1-year return at 44.57%, while Orchid Pharma has the lowest return at -34.27%.

Peers: The peers of Dishman Carbogen are Aarti Drugs, Sequent Scien., Hikal, Unichem Labs., RPG LifeScience., Guj. Themis Bio., Orchid Pharma, Gufic BioScience, and Advanced Enzyme.<BR><BR>Quality Snapshot: Excellent management risk is observed at RPG LifeScience, while Good management risk is found at Aarti Drugs, Hikal, Guj. Themis Bio., Gufic BioScience, and Advanced Enzyme, and the rest have Average or Below Average management risk. Growth is Below Average for Aarti Drugs, Sequent Scien., Hikal, RPG LifeScience, Guj. Themis Bio., Orchid Pharma, and Advanced Enzyme, while Average growth is seen at Unichem Labs. and Gufic BioScience, and the rest have Below Average growth. Capital Structure is Excellent for RPG LifeScience, Guj. Themis Bio., Gufic BioScience, and Advanced Enzyme, Good for Aarti Drugs and Unichem Labs., Average for Hikal, and Below Average for Sequent Scien., Dishman Carbogen, Orchid Pharma, and Zota Health Care.<BR><BR>Return Snapshot: RPG LifeScience has the highest 1-year return at 44.57%, while Orchid Pharma has the lowest at -34.27%, with Dishman Carbogen's own 1-year return at 57.24% being significantly higher than both. Additionally, Orchid Pharma and Advanced Enzyme have negative six-month returns.

Who are in the management team of Dishman Carbogen?

As of March 2022, the management team of Dishman Carbogen includes Janmejay R Vyas (Chairman), Deohooti J Vyas (Whole-time Director), Arpit J Vyas (Managing Director & CFO), and several independent directors, along with a Company Secretary. This team oversees the company's operations and governance.

As of March 2022, the management team of Dishman Carbogen includes the following individuals:<BR><BR>1. Janmejay R Vyas - Chairman (Non-Executive)<BR>2. Deohooti J Vyas - Whole-time Director<BR>3. Arpit J Vyas - Managing Director & CFO<BR>4. Sanjay S Majmudar - Independent Director<BR>5. Ashok C Gandhi - Independent Director<BR>6. Subir Kumar Das - Independent Director<BR>7. Rajendra S Shah - Independent Director<BR>8. Shrima Dave - Company Secretary & Compliance Officer<BR>9. Maitri K Mehta - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, along with a compliance officer, overseeing the company's operations and governance.

Who are the top shareholders of the Dishman Carbogen?

The top shareholders of Dishman Carbogen include Adimans Technologies LLP with 59.32%, individual investors with 25.31%, and Mukul Mahavir Agrawal holding 5.5%. Additionally, foreign institutional investors hold 9.49%, and mutual funds have a combined stake of 1.06%, with no pledged promoter holdings reported.

The top shareholders of Dishman Carbogen include the promoters, with Adimans Technologies LLP holding the highest stake at 59.32%. Additionally, individual investors collectively own 25.31% of the company. Among public shareholders, Mukul Mahavir Agrawal is notable with a holding of 5.5%. The company also has 61 foreign institutional investors (FIIs) holding 9.49% and 6 mutual fund schemes with a combined holding of 1.06%. There are no pledged promoter holdings reported.

How big is Dishman Carbogen?

As of 24th July, Dishman Carbogen Amcis Ltd has a market capitalization of 4,061.00 Cr, with net sales of 2,711.50 Cr and a net profit of 3.24 Cr for the latest four quarters. The balance sheet as of March 2024 shows shareholder's funds of 5,627.50 Cr and total assets of 9,570.62 Cr.

As of 24th July, Dishman Carbogen Amcis Ltd has a market capitalization of 4,061.00 Cr, categorizing it as a Small Cap company.<BR><BR>For the latest four quarters, the company reported net sales of 2,711.50 Cr and a net profit of 3.24 Cr.<BR><BR>As of March 2024, the balance sheet shows shareholder's funds amounting to 5,627.50 Cr and total assets of 9,570.62 Cr.

When is the next results date for Dishman Carbogen?

Dishman Carbogen is scheduled to declare its results on 04 November 2025.

Dishman Carbogen is scheduled to declare its results on 04 November 2025.

Is Dishman Carbogen overvalued or undervalued?

As of November 6, 2025, Dishman Carbogen is considered fairly valued with a PE ratio of 28.07, an EV to EBITDA of 10.39, and a Price to Book Value of 0.72, outperforming the Sensex with a 37.05% return over the past year.

As of 6 November 2025, Dishman Carbogen's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 28.07, an EV to EBITDA of 10.39, and a Price to Book Value of 0.72. <BR><BR>In comparison to its peers, Dishman Carbogen's PE ratio is lower than that of Sun Pharma, which stands at 35.02, and significantly lower than Divi's Lab at 79.09. However, it is on par with Cipla, which has a PE of 22.27, and Dr. Reddy's Labs at 17.42. Notably, Dishman Carbogen has outperformed the Sensex over the past year with a return of 37.05% compared to the Sensex's 3.65%, reinforcing its current valuation status.

How has been the historical performance of Dishman Carbogen?

Dishman Carbogen's historical performance shows steady growth in net sales from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025, with improved profitability indicators, including a profit after tax of INR 3.24 crore in March 2025. Total liabilities and assets increased, reflecting a stronger financial position, while cash flow from operations remained stable.

Answer:<BR>The historical performance of Dishman Carbogen shows a fluctuating trend in key financial metrics over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Dishman Carbogen's net sales have shown a steady increase from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025. The total operating income followed a similar trend, rising from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025. However, the total expenditure, excluding depreciation, increased from INR 1,809.32 crore in March 2022 to INR 2,242.56 crore in March 2025, impacting the operating profit, which saw a rise to INR 468.94 crore in March 2025 from INR 331.37 crore in March 2022. Despite this, the profit before tax turned positive at INR 19.31 crore in March 2025 after being negative in the previous years. The profit after tax also improved to INR 3.24 crore in March 2025 from a loss of INR 153.45 crore in March 2024. On the balance sheet, total liabilities increased to INR 9,986.34 crore in March 2025 from INR 8,634.20 crore in March 2022, while total assets rose to INR 9,986.34 crore in March 2025, indicating a growth in the company's financial position. Cash flow from operating activities remained relatively stable, with INR 375 crore in March 2025, while net cash inflow was recorded at INR 76 crore for the same period. Overall, Dishman Carbogen has shown signs of recovery and growth in its financial performance over the past few years.

Is Dishman Carbogen technically bullish or bearish?

As of December 2, 2025, the market trend for Dishman Carbogen has shifted to mildly bearish, indicated by bearish MACD readings and Bollinger Bands on the weekly chart, despite some short-term support from daily moving averages.

As of 2 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, supported by the weekly and monthly MACD readings, both indicating a bearish momentum. The Bollinger Bands show a bearish signal on the weekly chart, while the daily moving averages are mildly bullish, suggesting some short-term support. The KST and OBV are also mildly bearish on the weekly timeframe. Overall, the combination of these indicators points to a bearish sentiment in the current market environment for Dishman Carbogen.

Are Dishman Carbogen Amcis Ltd latest results good or bad?

The latest results for Dishman Carbogen Amcis Ltd are concerning, as the company achieved record sales of ₹719.80 crores but reported a net loss of ₹12.97 crores, indicating significant operational challenges and a negative profit margin. Overall, these results are considered bad, raising concerns about the company's profitability and operational efficiency.

The latest results for Dishman Carbogen Amcis Ltd are concerning. While the company reported its highest quarterly sales ever at ₹719.80 crores, it simultaneously recorded a significant net loss of ₹12.97 crores. This represents a dramatic decline in profitability, with a negative profit after tax (PAT) margin of -1.80%, marking the worst quarterly performance in terms of profitability in recent history.<BR><BR>The operating margin also saw a sharp contraction, decreasing by 710 basis points to 15.71%. This indicates substantial operational challenges and cost pressures that the company is facing. Despite the increase in sales, the inability to convert this revenue into profit raises serious questions about operational efficiency and margin sustainability.<BR><BR>Overall, the results reflect a troubling disconnect between revenue growth and profitability, leading to heightened concerns among investors about the company's operational health and future prospects. Given these factors, the latest results can be characterized as bad, highlighting significant issues that need to be addressed for any potential recovery.

Should I buy, sell or hold Dishman Carbogen Amcis Ltd?

Which are the latest news on Dishman Carbogen?

Why is Dishman Carbogen Amcis Ltd falling/rising?

As of 17-Mar, Dishman Carbogen Amcis Ltd's stock price is Rs 163.55, down 1.8%, with significant declines over the past month and year. Weak fundamentals, declining investor interest, and poor performance metrics are contributing to the stock's downward trend.

As of 17-Mar, Dishman Carbogen Amcis Ltd's stock price is falling, currently at Rs 163.55, which reflects a decrease of Rs 3.0 or 1.8%. The stock has underperformed its sector by 2.08% today and has touched an intraday low of Rs 159.75, marking a decline of 4.08%. <BR><BR>Over the past week, the stock has experienced a slight decline of 0.76%, while its performance over the past month shows a significant drop of 16.60%. Year-to-date, the stock has fallen by 34.03%, which is considerably worse than the Sensex's decline of 10.74% during the same period. Furthermore, the stock has generated a return of -22.98% over the past year, contrasting sharply with the Sensex's increase of 2.56%.<BR><BR>The company's fundamentals also indicate weaknesses contributing to the stock's decline. The Return on Capital Employed (ROCE) is low at 0.97%, and the company has shown poor long-term growth with net sales increasing at an annual rate of only 8.10% over the last five years. Additionally, the company has a high Debt to EBITDA ratio of 4.96 times, indicating a low ability to service its debt.<BR><BR>Investor participation is also waning, as evidenced by a 31.65% drop in delivery volume compared to the five-day average. Institutional investors have reduced their stake by 0.51% in the previous quarter, suggesting a lack of confidence in the company's prospects. <BR><BR>Overall, the combination of poor performance metrics, declining investor interest, and weak fundamentals are driving the stock price of Dishman Carbogen Amcis Ltd downward.

Why is Dishman Carbogen Amcis Ltd falling/rising?

As of 18-Mar, Dishman Carbogen Amcis Ltd's stock price is currently at Rs 171.85, reflecting a short-term rise of 5.07%. However, the stock has a negative long-term performance with a -21.53% return over the past year and weak fundamentals, raising concerns about its future stability.

As of 18-Mar, Dishman Carbogen Amcis Ltd's stock price is rising, currently at Rs 171.85, reflecting a change of 8.3 (5.07%) upwards. This increase can be attributed to its performance today, where the stock outperformed its sector by 4.8%. Additionally, it reached an intraday high of Rs 177.35, indicating positive trading momentum.<BR><BR>Despite this short-term rise, the stock has faced significant challenges over the longer term. Over the past year, it has generated a return of -21.53%, and year-to-date, it has declined by -30.68%. The company's fundamentals show weak long-term strength, with a low average Return on Capital Employed (ROCE) of 0.97% and a high Debt to EBITDA ratio of 4.96 times, which raises concerns about its ability to service debt.<BR><BR>Furthermore, there has been a noticeable decline in investor participation, with delivery volume falling by -16.01% against the 5-day average. Institutional investors have also reduced their stake by -0.51% in the previous quarter, indicating a lack of confidence among more knowledgeable investors.<BR><BR>In summary, while the stock is experiencing a rise in price today, the overall trend and fundamental indicators suggest significant underlying weaknesses that could impact its future performance.

Why is Dishman Carbogen Amcis Ltd falling/rising?

As of 19-Mar, Dishman Carbogen Amcis Ltd's stock price is declining, currently at Rs 160.90, reflecting a year-to-date drop of 35.09% and significant underperformance compared to the Sensex. Weak financial metrics, including a low ROCE and high debt levels, along with reduced institutional interest, further contribute to the stock's poor performance.

As of 19-Mar, Dishman Carbogen Amcis Ltd's stock price is falling, currently at Rs 160.90, which reflects a decrease of Rs 10.3 or 6.02%. The stock has underperformed the sector today by 3.87%, and it has touched an intraday low of Rs 160, marking a decline of 6.54%. Additionally, the stock is trading significantly lower than its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages.<BR><BR>In terms of broader performance, the stock has shown a year-to-date decline of 35.09%, which is substantially worse than the Sensex's decline of 12.92% over the same period. Over the past year, the stock has generated a return of -28.96%, while the Sensex has only declined by 1.65%. This trend indicates a consistent underperformance relative to the market.<BR><BR>The company's financial health also raises concerns, as evidenced by a weak Return on Capital Employed (ROCE) of 0.97% and a high Debt to EBITDA ratio of 4.96 times, which suggests a low ability to service debt. Furthermore, the company's profits have fallen sharply, with a reported PAT of Rs -12.97 crore, reflecting a staggering decline of 403.0%. Institutional investors have also reduced their stake in the company by 0.51% in the previous quarter, indicating a lack of confidence from those with more resources to analyze the company's fundamentals.<BR><BR>Overall, the combination of poor stock performance, weak financial metrics, and declining institutional interest contributes to the falling stock price of Dishman Carbogen Amcis Ltd.

Why is Dishman Carbogen Amcis Ltd falling/rising?

As of 20-Mar, Dishman Carbogen Amcis Ltd's stock price is Rs 158.85, down 0.94%, and nearing its 52-week low. The stock has underperformed significantly over the past year, with weak fundamentals and declining institutional investor confidence contributing to its current decline.

As of 20-Mar, Dishman Carbogen Amcis Ltd's stock price is falling, currently at Rs 158.85, reflecting a decrease of Rs 1.5 or 0.94%. The stock has been on a downward trend, having lost 7.21% over the last two days. Additionally, it is trading close to its 52-week low, just 2.86% away from Rs 154.3. <BR><BR>In terms of performance, the stock has underperformed its sector by 2.64% today and has shown a significant decline of 30.63% over the past year, compared to a mere 2.38% decline in the broader market index, Sensex. The stock's long-term fundamentals are weak, evidenced by a low Return on Capital Employed (ROCE) of 0.97% and a high Debt to EBITDA ratio of 4.96 times, indicating challenges in servicing debt.<BR><BR>Moreover, institutional investor participation has decreased, with a reduction of 0.51% in their stake over the previous quarter, which may reflect a lack of confidence in the company's prospects. Despite a substantial increase in profits by 233.1% over the past year, the stock's overall performance remains poor, with low growth in net sales and significant losses reported in the latest quarterly results. This combination of factors contributes to the stock's current decline.

Why is Dishman Carbogen Amcis Ltd falling/rising?

As of 23-Mar, Dishman Carbogen Amcis Ltd's stock price is at 142.85, down 9.96%, and has reached a 52-week low. The stock is underperforming its sector, showing weak fundamentals and declining investor interest, contributing to its bearish trend.

As of 23-Mar, Dishman Carbogen Amcis Ltd's stock price is falling, currently at 142.85, reflecting a change of -15.8 (-9.96%). The stock has been on a downward trend, having lost -16.38% over the last three days and hitting a new 52-week low of Rs. 141.05 today. This decline is further exacerbated by the stock's performance relative to the broader market, as it has underperformed its sector by -6.2%.<BR><BR>The stock's volatility is notable, with an intraday volatility of 7.27%, indicating significant price fluctuations. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. The delivery volume has also decreased significantly, falling by -62.68% compared to the 5-day average, indicating a drop in investor participation.<BR><BR>Financially, the company has shown weak long-term fundamentals, with a low Return on Capital Employed (ROCE) of 0.97% and a high Debt to EBITDA ratio of 4.96 times, which raises concerns about its ability to service debt. Furthermore, the company's profits have fallen sharply, with a PAT of Rs -12.97 crore, down by -403.0%. Institutional investors have also reduced their stakes by -0.51%, reflecting a lack of confidence in the company's prospects.<BR><BR>Overall, the combination of poor performance metrics, declining investor interest, and negative market sentiment contributes to the stock's current downward trajectory.

Why is Dishman Carbogen Amcis Ltd falling/rising?

As of 24-Mar, Dishman Carbogen Amcis Ltd's stock price is currently Rs 144.10, reflecting a recent upward trend after three days of decline, but it remains significantly down 41.87% year-to-date and shows weak long-term fundamentals. Despite increased retail investor interest, the overall outlook is cautious due to high debt levels and declining institutional participation.

As of 24-Mar, Dishman Carbogen Amcis Ltd's stock price is rising, with a current price of Rs 144.10, reflecting an increase of Rs 1.25 or 0.88%. This upward movement follows a trend reversal, as the stock has gained after three consecutive days of decline. Additionally, it opened with a significant gain of 3.26% today and reached an intraday high of Rs 148.9, which is a 4.24% increase.<BR><BR>Despite this positive movement, the stock has shown considerable weakness over the longer term. It is currently trading 2.12% away from its 52-week low and has experienced a substantial decline of 41.87% year-to-date. The stock's performance over the past year has also been poor, generating a return of -37.83%. Furthermore, it is trading below its moving averages across various time frames, indicating a bearish trend overall.<BR><BR>On a more positive note, there has been rising investor participation, with a delivery volume increase of 31.02% compared to the 5-day average, suggesting some renewed interest from retail investors. However, the company faces significant challenges, including weak long-term fundamentals, a high Debt to EBITDA ratio, and a decrease in institutional investor participation, which collectively contribute to a cautious outlook despite the recent price rise.

Why is Dishman Carbogen Amcis Ltd falling/rising?

As of 25-Mar, Dishman Carbogen Amcis Ltd's stock price is rising, currently at 153.80, reflecting a 6.73% increase. Despite recent gains, the long-term outlook is uncertain due to significant declines in year-to-date performance and concerns over fundamental weaknesses.

As of 25-Mar, Dishman Carbogen Amcis Ltd's stock price is rising, currently at 153.80, reflecting an increase of 9.7 (6.73%). This rise can be attributed to a performance today that has outperformed the sector by 4.84% and a consecutive gain over the last two days, where the stock has risen 7.67% in that period. Additionally, the stock reached an intraday high of Rs 154.85, indicating positive trading momentum.<BR><BR>Despite the recent gains, the stock has faced significant challenges over longer periods, with a year-to-date decline of 37.96% and a one-year return of -31.64%. However, the company has shown a substantial increase in profits, rising by 233.1%, which may contribute to a perception of value, as it is trading at a discount compared to its peers' average historical valuations. The low PEG ratio of 0.1 further suggests that the stock may be undervalued relative to its growth potential.<BR><BR>Nonetheless, there are concerns regarding the company's long-term fundamentals, including a weak Return on Capital Employed (ROCE) of 0.97% and a high Debt to EBITDA ratio of 4.96 times, which could hinder future growth. Additionally, falling participation from institutional investors, who have decreased their stake by 0.51%, raises questions about confidence in the stock's long-term prospects.<BR><BR>In summary, while Dishman Carbogen Amcis Ltd is experiencing a short-term rise in stock price due to recent performance and profit increases, the long-term outlook remains uncertain due to fundamental weaknesses and declining institutional interest.